63 completed, 46 unknown, 26 recruiting, 21 active not recruiting. 76 Not applicable, 43 Phase 2, 22 Phase 3, 13 Phase 1, 2 Early Phase 1.
Follow British Columbia Cancer Agency: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| High Dose Radiotherapy for Palliation (Hi-D) Palliative Radiotherapy - Metastases, Palliative Radiotherapy | Not applicable | Not yet recruiting | British Columbia Cancer Agency | 21 | 2027-03-01 | 2026-08-12 |
| The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial. Nivolumab & Ipilimumab, Nivolumab + Ipilimumab - Advanced Kidney Cancer | Phase 3 | Not yet recruiting | Guliz Ozgun | 142 | 2027-02-01 | 2026-10-01 |
| Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma External Beam Radiation Therapy - Orbital Lymphoma | Not applicable | Not yet recruiting | British Columbia Cancer Agency | 36 | 2026-12-01 | 2026-10-13 |
| A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies 68Ga-DOTATATE PET/CT, 18F-AmBF3-TATE PET/CT - Neuroendocrine Tumors, NET, Pheochromocytoma/Paraganglioma | Not yet recruiting | British Columbia Cancer Agency | 60 | 2026-11-30 | 2026-10-06 | |
| The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer enfortumab vedotin and pembrolizumab (EV/P) - Advanced Bladder Cancer | Phase 3 | Not yet recruiting | Guliz Ozgun | 224 | 2026-11-01 | 2026-10-01 |
| Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life Hand grip strength assessments using a dynamometer - Pancreatic Ductal Adenocarcinoma (PDAC), Hand Grip Strength | Not applicable | Recruiting | British Columbia Cancer Agency | 50 | 2026-08-13 | 2026-09-15 |
| Single vs Hypofractionated Irradiation For Timely Access to Partial Breast Radiotherapy Multiple Fraction PBI, Single Fraction PBI - Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Not applicable | Recruiting | British Columbia Cancer Agency | 60 | 2026-06-08 | 2026-08-26 |
| HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG Oral FDG scan - Multiple Cancers, Multiple Indications Cancer | Not applicable | Active not recruiting | British Columbia Cancer Agency | 27 | 2026-02-10 | 2026-09-29 |
| First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients. Sacituzumab Govitecan (SG) - Advanced Triple Negative Breast Cancer, Breast Cancer Metastatic | Phase 2 | Recruiting | Nathalie Levasseur | 24 | 2026-01-20 | 2026-10-06 |
| Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers Stereotactic ablative radiotherapy (SABR), Palliative radiotherapy - Oligoprogression, Oligometastatic Disease | Not applicable | Recruiting | British Columbia Cancer Agency | 194 | 2025-12-04 | 2025-12-15 |
| Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment Genetic testing, Optional biopsy, Tissue collection - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Not applicable | Recruiting | British Columbia Cancer Agency | 200 | 2025-11-28 | 2026-09-16 |
| Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer Stereotactic Body Radiation Therapy (SBRT) - Prostate CA | Phase 2 | Recruiting | British Columbia Cancer Agency | 100 | 2025-09-04 | 2026-06-24 |
| Dynamic Whole Body PET/ MRI 68Ga-HTK03149 - Prostatic Cancer | Withdrawn | British Columbia Cancer Agency | 2025-08-01 | 2025-01-08 | ||
| The Canadian Lung Outcomes in Users of Vaping Devices Study Small Airways Diseases, Vaping | Recruiting | University of British Columbia | 500 | 2025-07-25 | 2026-03-30 | |
| SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors SABR - Breast Cancer, Metastases | Not applicable | Not yet recruiting | British Columbia Cancer Agency | 40 | 2025-07-01 | 2025-04-24 |
| Time Restricted Eating in Haematological Malignancies Time-Restricted Eating - Cancer, Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | British Columbia Cancer Agency | 75 | 2025-06-01 | 2025-06-13 |
| DOTATATE PET for Meningioma Radiation Planning DOTATATE-PET scan - Meningioma | Not applicable | Not yet recruiting | British Columbia Cancer Agency | 36 | 2025-06-01 | 2025-04-22 |
| Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer Sacituzumab Govitecan - Breast Cancer | Phase 2 | Recruiting | British Columbia Cancer Agency | 20 | 2025-03-31 | 2025-06-25 |
| Methadone to Treat Painful Chemotherapy Induced Peripheral Neuropathy methadone, duloxetine - Chemotherapy-induced Peripheral Neuropathy | Phase 2 / Phase 3 | Recruiting | University of British Columbia | 50 | 2025-03-21 | 2025-03-27 |
| CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies CLIC-2201 - B-Cell Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Recruiting | British Columbia Cancer Agency | 24 | 2025-01-02 | 2026-10-14 |
Showing 20 of 192. Sign in to see all of them.
Prostatic Neoplasms (30) · Breast Neoplasms (29) · Neoplasms (22) · Lung Neoplasms (13) · Neoplasm Metastasis (13) · Uterine Cervical Neoplasms (13) · Precancerous Conditions (11) · Carcinoma, Non-Small-Cell Lung (10) · Uterine Cervical Dysplasia (10) · Ovarian Neoplasms (8) · Brain Neoplasms (6) · Colorectal Neoplasms (6) · Small Cell Lung Carcinoma (6) · Neuroendocrine Tumors (5) · Carcinoid Tumor (4)
Exercise (4) · Prednisone (4) · Radiosurgery (4) · Abiraterone Acetate (3) · Bevacizumab (3) · Colposcopy (3) · Doxorubicin (3) · Magnetic Resonance Spectroscopy (3) · enzalutamide (3) · Aromatase Inhibitors (2) · Budesonide (2) · Cyclophosphamide (2) · Fluorodeoxyglucose F18 (2) · Lidocaine (2) · Metformin (2)
Canada (177) · United States (5) · Australia (2) · Austria (1) · Ireland (1) · United Kingdom (1)
Francois Benard, MD (10) · Stephen Lam, MD (8) · Kim N Chi, MD (6) · Daniel J Renouf, MD (5) · Cheryl Ho, MD (4) · Hagen Kennecke, MD (4) · Stephen Chia, MD (4) · William J Morris, MD (4) · Juanita M Crook, MD (3) · Kristin L Campbell, PhD (3) · Alan M Nichol, MD (2) · Alan Nichol, MD (2) · Juanita Crook, MD (2) · Kim Chi, MD (2) · Kristin Campbell, PhD (2)
PMID 16182464, PMID 31481506, PMID 40373801, PMID 18285602, PMID 18618604, PMID 18930602, PMID 19255320, PMID 19255321, PMID 21620645, PMID 21788033, PMID 21862407, PMID 22019237, PMID 22026481, PMID 23611660, PMID 23835717, PMID 23922302, PMID 24004118, PMID 24386300, PMID 24719431, PMID 25367403, PMID 25630357, PMID 25819287, PMID 26170884, PMID 26573073, PMID 26678660, PMID 26961146, PMID 26991631, PMID 27142184, PMID 27193737, PMID 27281710, PMID 27486205, PMID 27617968, PMID 28884636, PMID 28950338, PMID 29055736, PMID 29092957, PMID 29157121, PMID 29398594, PMID 29437940, PMID 29551231, PMID 30286739, PMID 30591354, PMID 30659040, PMID 30833417, PMID 31068372, PMID 31160355, PMID 31371350, PMID 31660894, PMID 31727538, PMID 31894702
P01CA082710 (4), P01CA096964 (2), R01CA103830 (2), R01CA221918 (1), U01CA096109 (1)